

# K N Roy Chengappa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11564416/publications.pdf>

Version: 2024-02-01

47  
papers

2,443  
citations

279798

23  
h-index

243625

44  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2340  
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 170-177.	2.0	2
2	Group teletherapy for first-episode psychosis: Piloting its integration with coordinated specialty care during the COVID-19 pandemic. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2021, 94, 382-389.	2.5	22
3	ECT for a pregnant patient with bipolar disorder in the COVID-19 Era: A clinical conundrum. <i>Bipolar Disorders</i> , 2021, 23, 524-527.	1.9	3
4	From Office-Based Treatment to Telehealth: Comparing Clinical Outcomes and Patient Participation in a Psychiatric Intensive Outpatient Program with a Large Transdiagnostic Sample. <i>Telemedicine Journal and E-Health</i> , 2021, , .	2.8	3
5	Racial Differences in S100b Levels in Persons with Schizophrenia. <i>Psychiatric Quarterly</i> , 2020, 91, 137-145.	2.1	8
6	Ensuring care for clozapine-treated schizophrenia patients during the COVID-19 pandemic. <i>Schizophrenia Research</i> , 2020, 222, 499-500.	2.0	14
7	Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions. <i>Schizophrenia Research</i> , 2020, 222, 532-533.	2.0	26
8	Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia. <i>Neuropsychopharmacology</i> , 2018, 43, 1334-1342.	5.4	17
9	A cognitive perspective on mood. <i>Bipolar Disorders</i> , 2018, 20, 180-180.	1.9	0
10	Adjunctive Use of a Standardized Extract of <em>Withania somnifera</em> (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	44
11	The Potential Utility of Ashwagandha for Improving Cognitive Dysfunction in Persons with Bipolar or Other Neurocognitive Disorders. , 2017, , 345-371.		0
12	All aboard: the Journal's journey to broader contentment. <i>Bipolar Disorders</i> , 2017, 19, 412-413.	1.9	1
13	Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. <i>Nicotine and Tobacco Research</i> , 2015, 18, ntv085.	2.6	16
14	Subtle changes in thyroid indices during a placebo-controlled study of an extract of <i>Withania somnifera</i> in persons with bipolar disorder. <i>Journal of Ayurveda and Integrative Medicine</i> , 2014, 5, 241.	1.7	21
15	Varenicline for Smoking Cessation in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 765-772.	2.2	74
16	Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. <i>Addiction</i> , 2013, 108, 1962-1968.	3.3	19
17	Randomized Placebo-Controlled Adjunctive Study of an Extract of <i>Withania somnifera</i> for Cognitive Dysfunction in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1076-1083.	2.2	89
18	A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. <i>Schizophrenia Research</i> , 2012, 142, 145-152.	2.0	69

#	ARTICLE	IF	CITATIONS
19	Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic. <i>General Hospital Psychiatry</i> , 2012, 34, 660-664.	2.4	35
20	<i>Atypical mood stabilizers</i>: a new role for neuroleptics?. <i>Bipolar Disorders</i> , 2011, 13, 583-586.	1.9	12
21	Hypomania: hype <i>or</i> mania?. <i>Bipolar Disorders</i> , 2010, 12, 758-763.	1.9	25
22	Editorial. <i>Bipolar Disorders</i> , 2010, 12, 757-757.	1.9	0
23	Long term outcomes in persons with bipolar disorderâ€”Developing versus developed countries. <i>Asian Journal of Psychiatry</i> , 2010, 3, 49.	2.0	1
24	Lithium specificity in bipolar illness: a classic agent for the classic disorder. <i>Bipolar Disorders</i> , 2009, 11, 34-44.	1.9	98
25	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. <i>Asian Journal of Psychiatry</i> , 2009, 2, 106-111.	2.0	4
26	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 193-194.	1.4	2
27	Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. <i>Bipolar Disorders</i> , 2008, 10, 566-579.	1.9	40
28	Bipolar Disorder and the Metabolic Syndrome. <i>CNS Drugs</i> , 2008, 22, 655-669.	5.9	115
29	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 247-248.	1.4	12
30	Weight gain and metabolic issues of medicines used for bipolar disorder. <i>Current Psychiatry Reports</i> , 2007, 9, 521-528.	4.5	27
31	Adjunctive Topiramate Therapy in Patients Receiving a Mood Stabilizer for Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1698-1706.	2.2	64
32	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. <i>Bipolar Disorders</i> , 2005, 7, 68-76.	1.9	43
33	The prevalence of the metabolic syndrome in patients with schizoaffective disorder â€” bipolar subtype. <i>Bipolar Disorders</i> , 2004, 6, 314-318.	1.9	115
34	Treatment of bipolar mania with atypical antipsychotics. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, S17-S25.	2.8	21
35	The Off-Label Use of Clozapine in Adolescents with Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 57-63.	1.3	50
36	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser <i>v.</i> mood stabiliser alone. <i>British Journal of Psychiatry</i> , 2004, 184, 337-345.	2.8	288

#	ARTICLE	IF	CITATIONS
37	Dosage and Administration Issues of Antipsychotic Agents (and Adjunctive Medicines) in the Acute Stabilization of Psychoses. <i>CNS Spectrums</i> , 2004, 9, 6-10.	1.2	112
38	Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. <i>Bipolar Disorders</i> , 2003, 5, 1-5.	1.9	74
39	A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. <i>Clinical Therapeutics</i> , 2003, 25, 530-541.	2.5	56
40	A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 187-194.	1.9	21
41	Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. <i>Archives of General Psychiatry</i> , 2002, 59, 62.	12.3	410
42	Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review. <i>Clinical Therapeutics</i> , 2002, 24, 1576-1584.	2.5	108
43	The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 437-440.	4.8	16
44	Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. <i>European Psychiatry</i> , 2001, 16, 186-190.	0.2	78
45	Efectos a largo plazo del topiramato sobre la inestabilidad del estado de Ánimo bipolar, el cambio de peso y el control glucémico: una serie clÁnica. <i>European Psychiatry (Ed Espa±ola)</i> , 2001, 8, 361-365.	0.0	0
46	Anticholinergic Differences Among Patients Receiving Standard Clinical Doses of Olanzapine or Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 311-316.	1.4	68
47	Clozapine Reduces Severe Self-Mutilation and Aggression in Psychotic Patients With Borderline Personality Disorder. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 477-484.	2.2	117